Abstract
The primary objective of this study was to evaluate the incremental cost-utility ratio (ICUR) for the adjuvant treatment of patients with resected EC/GEJC tumour in Canada. This analysis is based on outcomes of the phase 3 clinical trial, CheckMate 577, in which patients with resected EC/GEJC had statistically significant and clinically meaningful improvement in its primary endpoint, disease-free survival (DFS), versus placebo with an acceptable safety profile following neoadjuvant chemoradiotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
